Patent Granted for MoAbs Used in Neoprobe's RIGScan Products

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

DUBLIN, Ohio--Neoprobe Corporation has announced that a patent granted to Jeffrey Schlom, PhD, of the National Cancer Institute, and David Colcher, PhD, of the University of Nebraska Medical Center, covers claims to composition of matter for a large group of second-generation monoclonal antibodies that target the tumor-associated antigen TAG-72.

DUBLIN, Ohio--Neoprobe Corporation has announced that a patentgranted to Jeffrey Schlom, PhD, of the National Cancer Institute,and David Colcher, PhD, of the University of Nebraska MedicalCenter, covers claims to composition of matter for a large groupof second-generation monoclonal antibodies that target the tumor-associatedantigen TAG-72.

Neoprobe holds an exclusive global license for use of these antibodieswith its RIGS technology for surgical detection and treatmentof cancer. The antibodies named in the patent include CC49, acomponent of Neo-probe's first commercial product, RIGScan CR49,currently under investigation for colorectal cancer.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Related Content